REPLIMUNE GROUP INC.

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

03 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

20 May 2021 08:00:02 By Nasdaq GlobeNewswire

Replimune Appoints Tanya Lewis as Chief Development Operations Officer

10 May 2021 08:00:00 By Nasdaq GlobeNewswire

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

05 May 2021 07:00:01 By Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on June 3, 2021

28 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer

21 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

12 Apr 2021 16:01:00 By Nasdaq GlobeNewswire

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

11 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

Replimune to Present at Three Upcoming Investor Conferences

04 Mar 2021 08:00:02 By Nasdaq GlobeNewswire

Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference

18 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

04 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones

11 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference

06 Jan 2021 08:00:01 By Nasdaq GlobeNewswire

Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

05 Jan 2021 08:00:02 By Nasdaq GlobeNewswire